Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Terofenamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 14/20 | 0.69 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.61 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.61 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.61 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.61 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.58 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | FABP2 | P12104 | 1/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terofenamate SCHEMBL26088 | 0.99 | METTL3 (0.84) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL29483481 | 0.99 | METTL3 (0.84) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL6726614 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL18575664 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL14247884 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL3241449 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL8814628 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL1206761 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL22612217 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL6851974 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11548852-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4074728-A1 | MODIFIED PEPTIDES COMPRISING AN AZIDO GROUP | Sutro Biopharma, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| EP-3584255-B1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA INC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200361870-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10730837-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-2890402-B1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20190047958-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2019-02-14 | — | — | US | disclosed |
| CN-109251444-A | Plasticizer for polyvinyl chloride and preparation method thereof | 长沙小如信息科技有限公司 | 2019-01-22 | — | — | CN | disclosed |
| US-10112900-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170267637-A1 | Modified Amino Acids | SUTRO BIOPHARMA, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170260137-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9682934-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| CN-106710676-A | Submarine communication composite cable with modified polyvinyl chloride sheath | 芜湖航天特种电缆厂股份有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104981254-A | Modified amino acids comprising an azido group | SUTRO BIOPHARMA INC | 2015-10-14 | — | — | CN | disclosed |
| EP-2890402-A1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | Sutro Biopharma, Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| CN-104592683-A | Flame-retardant polyvinyl chloride for cable and preparation method of flame-retardant polyvinyl chloride | Wuhu Hangtian Special Cable Factory | 2015-05-06 | — | — | CN | disclosed |
| WO-2014046544-A1 | SUBSTITUTED 3-HETEROARYLOXY-3-(HETERO)ARYL-PROPYLAMINES AS SEROTONIN TRANSPORTER AND SEROTONIN HT2C RECEPTOR MODULATORS | AAPA B.V. (NL) | 2014-03-27 | — | — | WO | disclosed |
| US-20140066598-A1 | Modified Amino Acids | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014036492-A1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361870-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-11548852-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-20170267637-A1 | Modified Amino Acids | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-10112900-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-20140066598-A1 | Modified Amino Acids | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-10730837-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-20170260137-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
| US-20190047958-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | PTGS2 4774/4885TTR 271/4885CHRM1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.